NCT04580420 - Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

December 30, 2031

Study Completion Date

January 30, 2032

Conditions

Primary Hyperoxaluria Type 1End Stage Renal Disease

Interventions

DRUG

DCR-PHXC

Monthly dosing throughout study period

Trial Locations (18)

2025

NOT_YET_RECRUITING

Clinical Trial Site, Casablanca

10016

RECRUITING

Clinical Trial Site, New York

38320

WITHDRAWN

Clinical Trial Site, Santa Cruz de Tenerife

53127

RECRUITING

Clinical Trial Site, Bonn

55905

RECRUITING

Clinical Trial Site, Rochester

69120

RECRUITING

Clinical Trial Site, Heidelberg

69677

WITHDRAWN

Clinical Trial Site, Bron

75019

WITHDRAWN

Clinical Trial Site, Paris

94143

RECRUITING

Clinical Trial Site, San Francisco

410469

WITHDRAWN

Clinical Trial Site, Oradea

410562

WITHDRAWN

Clinical Trial Site, Oradea

02115

RECRUITING

Clinical Trial Site, Boston

00165

RECRUITING

Clinical Trial Site, Roma

00001

RECRUITING

Clinical Trial Site, Beirut

08035

RECRUITING

Clinical Trial Site, Barcelona

+971

NOT_YET_RECRUITING

Clinical Trial Site, Dubai

NWG 2Q3

RECRUITING

Clinical Trial Site, London

WC1N3JH

RECRUITING

Clinical Trial Site, London

All Listed Sponsors

lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY